ATE322261T1 - Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten - Google Patents

Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten

Info

Publication number
ATE322261T1
ATE322261T1 AT02783094T AT02783094T ATE322261T1 AT E322261 T1 ATE322261 T1 AT E322261T1 AT 02783094 T AT02783094 T AT 02783094T AT 02783094 T AT02783094 T AT 02783094T AT E322261 T1 ATE322261 T1 AT E322261T1
Authority
AT
Austria
Prior art keywords
acid
hydroxyolic
medications
production
similar compounds
Prior art date
Application number
AT02783094T
Other languages
German (de)
English (en)
Inventor
Ruiz Pablo Vicente Cam Escriba
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Application granted granted Critical
Publication of ATE322261T1 publication Critical patent/ATE322261T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02783094T 2001-10-11 2002-10-09 Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten ATE322261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.

Publications (1)

Publication Number Publication Date
ATE322261T1 true ATE322261T1 (de) 2006-04-15

Family

ID=8499164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02783094T ATE322261T1 (de) 2001-10-11 2002-10-09 Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten

Country Status (13)

Country Link
US (3) US20050014831A1 (https=)
EP (1) EP1435235B1 (https=)
JP (1) JP4737931B2 (https=)
CN (3) CN100471492C (https=)
AT (1) ATE322261T1 (https=)
BR (1) BRPI0213165B8 (https=)
CA (1) CA2463348C (https=)
DE (1) DE60210488T2 (https=)
ES (2) ES2186576B1 (https=)
MX (1) MXPA04003255A (https=)
PT (1) PT1435235E (https=)
RU (1) RU2310445C2 (https=)
WO (1) WO2003030891A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
CN101570481B (zh) * 2008-04-30 2012-02-01 上海医药工业研究院 一种多羟基长链脂肪酸及其分离提取方法和在抑制芳香化酶活性中的应用
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
WO2011089265A1 (en) 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
CN101985420B (zh) * 2010-01-29 2014-04-30 苏州润新生物科技有限公司 油酸酯及其制备方法和在制备用于治疗高血压及其并发症的药物中的应用
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
EP2805717A4 (en) * 2012-01-19 2015-06-10 Nippon Suisan Kaisha Ltd APPETITE IN HOUR
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
NZ706067A (en) * 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
WO2016062746A1 (en) * 2014-10-21 2016-04-28 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
US10756968B2 (en) 2015-01-26 2020-08-25 Rapid7, Inc. Network resource management devices methods and systems
CN121041235A (zh) * 2025-11-03 2025-12-02 云南绿A生物工程有限公司 一种藻蓝蛋白软胶囊及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61297A (ja) * 1984-06-12 1986-01-06 日本油脂株式会社 オレイン酸の製造法
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
JPS6344843A (ja) * 1986-08-13 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
CN1118228A (zh) * 1995-03-16 1996-03-13 姜训书 松籽果酱
CN1118218A (zh) * 1995-03-16 1996-03-13 姜训书 松籽油的制作方法及松籽保健食用油
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
ES2192221T3 (es) * 1995-10-30 2003-10-01 Oleoyl Estrone Developments S Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso.
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
DE19727636C1 (de) * 1997-06-28 1998-11-19 Rwe Dea Ag Verfahren zur Herstellung von 2-Alkylcarbonsäuren
CN1212867A (zh) * 1997-09-29 1999-04-07 宋凤亭 防治心脑血管疾病的组合物
NO308197B1 (no) * 1998-01-21 2000-08-14 Fideline Sammensetning og oppløsning derav for Õ minske stress, angst og agressivitet hos pattedyr inneholdende en blanding av fettsyrer eller derivater derav
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB2389788B (en) * 2000-12-23 2005-07-20 Univ Creighton Methods for inducing apoptosis and inhibiting proliferation in cancer cells
DE10130491A1 (de) * 2001-06-25 2003-04-17 Heirler Horst Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas

Also Published As

Publication number Publication date
BR0213165A (pt) 2004-09-14
ES2186576B1 (es) 2004-09-16
DE60210488T2 (de) 2006-12-14
ES2186576A1 (es) 2003-05-01
US20090082446A1 (en) 2009-03-26
BRPI0213165B8 (pt) 2021-05-25
CA2463348A1 (en) 2003-04-17
WO2003030891A1 (es) 2003-04-17
JP2005527479A (ja) 2005-09-15
CN101259121A (zh) 2008-09-10
CN100471492C (zh) 2009-03-25
JP4737931B2 (ja) 2011-08-03
MXPA04003255A (es) 2005-01-25
CA2463348C (en) 2011-04-05
CN1688302A (zh) 2005-10-26
BRPI0213165B1 (pt) 2018-01-23
US20050014831A1 (en) 2005-01-20
US8778995B2 (en) 2014-07-15
CN101259122A (zh) 2008-09-10
CN101259122B (zh) 2011-04-06
RU2004114229A (ru) 2005-04-20
ES2261752T3 (es) 2006-11-16
PT1435235E (pt) 2006-08-31
US7851507B2 (en) 2010-12-14
EP1435235B1 (en) 2006-04-05
EP1435235A1 (en) 2004-07-07
CN101259121B (zh) 2011-04-06
US20110136906A1 (en) 2011-06-09
RU2310445C2 (ru) 2007-11-20
DE60210488D1 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
ATE322261T1 (de) Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten
CA2469813A1 (en) Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
BR0313790A (pt) Compostos de amida de ácido carboxìlico com efeito antagonista mch, medicamentos contendo estes compostos e processos para sua preparação
UY28050A1 (es) Nuevos compuestos de alquino con efecto antagonico de la hcm y medicamentos que contienen estos compuestos.
CY1114582T1 (el) Παραγωγα αλκυνυλιου ως ρυθμιστες μεταβολοτροπων υποδοχεων γλουταμινικου οξεος
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
DK0955294T3 (da) Imidazolylalkensyre
EP2062898A3 (de) Spirocyclische Cyclohexan-Derivate
ATE335748T1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
DE602006019880D1 (de) Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten
EP1489077A4 (en) 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
ATE427932T1 (de) 11beta-hsd1-inhibitoren
DE60231202D1 (de) Kondensierte heterozyklische verbindungen
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
DE502005010170D1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
WO2006053039A3 (en) Hydroxybenzoate salts of metanicotine compounds
BG101867A (bg) Бензотиазиндиоксиди като антагонисти на ендотелин
ATE409473T1 (de) Cyclopropyl und cyclobutyl epothilon analoge
MX2009005507A (es) Derivados de espiro-piperidina.
AU2003274686A1 (en) Inhibitors of the gpib -vwf interaction, their preparation and use
CA2534317A1 (en) Benzimidazole acetonitriles
ATE445617T1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
DE69618050D1 (de) Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
UY28689A1 (es) Nuevos compuestos amida con actividad antagonista de mch y medicamentos que contienen estos compuestos.
NO20082127L (no) Antagonister mot interaksjon av PF4 og Rantes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1435235

Country of ref document: EP